Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;27(4):2101196.
doi: 10.2807/1560-7917.ES.2022.27.4.2101196.

Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022

Dirk Eggink  1 , Stijn P Andeweg  1 , Harry Vennema  1 , Noortje van Maarseveen  2   3 , Klaas Vermaas  2 , Boris Vlaemynck  4 , Raf Schepers  4 , Arianne B van Gageldonk-Lafeber  1 , Susan van den Hof  1 , Chantal Bem Reusken  1 , Mirjam J Knol  1
Affiliations

Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022

Dirk Eggink et al. Euro Surveill. 2022 Jan.

Abstract

Infections with the Omicron SARS-CoV-2 variant are rapidly increasing worldwide. Among 174,349 SARS-CoV-2-infected individuals (≥ 12 years), we observed an increased risk of S gene target failure, predictive of the Omicron variant, in vaccinated (odds ratio (OR): 3.6; 95% confidence interval (CI): 3.4-3.7) and previously infected individuals (OR: 4.2; 95% CI: 3.8-4.7) compared with infected naïve individuals. This suggests vaccine- or infection-induced immunity against SARS-CoV-2 infections is less effective against the Omicron than the Delta variant.

Keywords: SARS-CoV-2 Omicron Variant of Concern Vaccine escape; air-borne infections; epidemiology; laboratory; severe acute respiratory syndrome - SARS; vaccines and immunisation; viral infections.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure
Figure
Number of included COVID-19 cases and percentage of S gene target failures by immune status, the Netherlands, 22 November 2021–19 January 2022 (n = 174,349)
See this image and copyright information in PMC

References

    1. World Health Organization (WHO). Tracking SARS-CoV-2 variants. Geneva: WHO. [Accessed: 30 Dec 2021]. Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants
    1. European Centre for Disease Prevention and Control (ECDC). Epidemiological update: Omicron variant of concern (VOC) – data as of 16 December 2021 (12:00). Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/news-events/epidemiological-update-omicron...
    1. Barnard RC, Davies N, Pearson CAB, Jit M, Edmunds J. Modelling the potential consequences of the Omicron SARS-CoV-2 variant in England | Centre for Mathematical Modelling of Infectious Diseases Repository. London: London School of Hygiene & Tropical Medicine; 2021. Preprint. Available from: https://cmmid.github.io/topics/covid19/omicron-england.html
    1. European Centre for Disease Prevention and Control (ECDC). Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 20 January 2022) EU/EEA. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/news-events/weekly-epidemiological-update-...
    1. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2021. 10.1038/s41586-021-04387-1 - DOI - PMC - PubMed

Substances

Supplementary concepts